Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

(2019) Adam Cuker et al.   Multiple Sclerosis Journal

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

(2019) Richard Phelps et al.   Multiple Sclerosis Journal

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Alemtuzumab CARE-MS II 5-year follow-up

(2017) Alasdair J. Coles et al.   NEUROLOGY

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

(2017) Tjalf Ziemssen et al.   Therapeutic Advances in Neurological Disorders

The importance of collecting structured clinical information on multiple sclerosis

(2016) Tjalf Ziemssen et al.   BMC Medicine

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS

(2016) Steffen Pfeuffer et al.   NEUROLOGY

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis

(2013) X. Zhang et al.   JOURNAL OF IMMUNOLOGY

Effective Strategies for Maintaining Research Participation in Clinical Trials

(2012) Allen Zweben et al.   DRUG INFORMATION JOURNAL

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

(2010) Joanne L. Jones et al.   BRAIN

Long-term follow-up of clinical trials of multiple sclerosis therapies

(2010) M. S. Freedman   NEUROLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE